Showing 1001-1010 of 1057 results for "".
- Seizure Risk High in People with Alzheimer’s Diseasehttps://practicalneurology.com/news/seizure-risk-high-in-people-with-alzheimers-disease/2468967/Data presented at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 show that people living with Alzheimer’s disease (AD) have epileptic seizures up to 6.5 times more often than those without AD. People with dementia are also at higher risk for recu
- Different Risk Factors and Progression of Alzheimer’s Disease in Women Have Implications for Diagnosis and Carehttps://practicalneurology.com/news/different-risk-factors-and-progression-of-alzheimers-disease-in-women-have-implications-for-diagnosis-and-care/2468965/Research reported at the Alzheimer’s Association International Conference (AAIC) in Los Angeles July 14-18, 2019 identifies a number of differences in risk for and progression of Alzheimer’s disease (AD) in women, including sex-specific genes, structural brain network differences, and
- Women With Migraine More Likely to Have Babies With Colichttps://practicalneurology.com/news/women-with-migraine-more-likely-to-have-babies-with-colic/2468964/At the American Headache Society’s 61st Annual Meeting July 11-14 in Philadephia, PA, Dr. Amy Gelfand, associate professor of neurology and director of the pediatric headache program at the University of California, San Francisco, received the 2019 Harold G. Wolff Lecture Award. This award
- Healthy Lifestyle Choices May Decrease Dementia Risk Even for People With Genetic Predispositions to Alzheimer’s Diseasehttps://practicalneurology.com/news/healthy-lifestyle-choices-may-decrease-dementia-risk-even-for-people-with-genetic-predispositions-to-alzheimers-disease/2468958/Data reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 and published today in JAMA, suggest lifestyle modifications may reduce risk of developing Alzheimer’s di
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Sensory Deficits Increase Risk of Dementia for Older Adultshttps://practicalneurology.com/news/sensory-deficits-increase-risk-of-dementia-for-older-adults/2468956/New research suggests that sensory deficits may be associated with an increased risk of developing both all-cause dementia and Alzheimer’s disease (AD) dementia. In a study from the University of Washington School of Public Health, 2,827 individuals, age 75 or more, who had
- First Participant Enrolled in Study of ENT-01 for Parkinson's Disease Dementiahttps://practicalneurology.com/news/first-participant-enrolled-in-study-of-ent-01-for-parkinsons-disease-dementia/2468938/The first participant is enrolled in a clinical study of ENT-01(Enterin, Philadelphia, PA), a compound designed to reverse neurologic symptoms associated with Parkinson’s disease dementia (PDD). The aim of the DEMET study, an open-label multi-center trial, is to enroll 30 participants with
- Schedule IV Designation For Solriamfetol, a New Treatment for Excessive Daytime Sleepiness in Narcolepsy or OSAhttps://practicalneurology.com/news/schedule-iv-designation-for-solriamfetol-a-new-treatment-for-excessive-daytime-sleepiness-in-narcolepsy-or-osa/2468931/The Drug Enforcement Agency DEA has designated solriamfetol (Sunosi; Jazz Pharmaceuticals, Philadelphia, PA) a schedule IV agent, meaning that it has low potential for abuse or dependence. Solriamfetol was approved for treatment of excessive daytime sleepiness associated with narcolepsy or obstru
- Minimally Invasive Removal of Deep Subcortical Hemorrhagehttps://practicalneurology.com/news/minimally-invasive-removal-of-deep-subcortical-hemorrhage/2468770/Minimally invasive techniques have been used to treat deep subcortical hemorrhages successfully. In 2 abstracts, presented at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA, minimally invasive parafascicular surgery (MIPS) with tubular retracto
- FDA Approves Solriamfetol for Treatment of Excessive Daytime Sleepinesshttps://practicalneurology.com/news/httpswwwfdagovdrugsdefaulthtm/2468797/The Food and Drug Administration (FDA) has approved solriamfetol (Sunosi; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults with excessive daytime sleepiness (EDS)associated with narcolepsy or obstructive sleep apnea (OSA). Solriamfetol is a dual dopamine and norepinephrine reupt